Uniklinikum Salzburg
- Address
- lock Available on a paid plan
Nervous System Diseases
The department leverages advanced neuroimaging to enhance diagnosis and guide treatment of brain and spinal disorders.
- Acute ischemic stroke with incomplete reperfusion
- Primary generalized tonic‑clonic seizures
- Early Parkinson’s disease
- Primary progressive multiple sclerosis
- Pediatric brain tumors such as medulloblastoma
Ongoing trials aim to evaluate novel therapeutic agents and device‑based interventions, seeking to improve functional recovery and long‑term neurological outcomes.
Neoplasms
Cutting‑edge imaging supports the assessment of solid and hematologic cancers across all stages.
- Advanced breast cancer (ER+/HER2‑)
- Non‑small cell lung cancer with molecular alterations
- Melanoma, including high‑risk resected disease
- Prostate cancer, localized and metastatic
- Pediatric sarcomas such as Ewing sarcoma
- Acute myeloid leukemia and related myelodysplastic syndromes
Studies focus on targeted therapies, immunotherapies, and combination regimens to increase survival and reduce disease recurrence.
Cardiovascular Diseases
Research integrates vascular imaging with clinical evaluation to address cardiovascular risk and heart failure.
- Chronic heart failure with reduced ejection fraction
- Atherosclerotic cardiovascular disease (ASCVD)
- Elevated lipoprotein(a) levels
- Hypertension
- Atrial fibrillation with stroke risk
Clinical trials test new pharmacologic agents, device‑based therapies, and lifestyle interventions to lower morbidity and mortality.
Immune System Diseases
The site investigates immune‑mediated conditions, employing biomarkers to guide therapy selection for inflammatory and autoimmune disorders.
- Crohn’s disease
- Ulcerative colitis
- Atopic dermatitis (moderate to severe)
- Systemic lupus erythematosus
- Rare skin disorders such as Netherton syndrome
Trials evaluate biologics, JAK inhibitors, and novel small molecules, aiming to achieve durable remission and improve quality of life.
Respiratory Tract Diseases
Focused investigations target chronic lung conditions, utilizing functional imaging and patient‑reported outcomes to assess respiratory health.
- Severe eosinophilic asthma
- Idiopathic pulmonary fibrosis
- Chronic obstructive pulmonary disease exacerbations
- Allergic rhinitis associated with asthma
Studies compare inhaled therapies, antifibrotic agents, and combination regimens to reduce exacerbations and preserve lung function.
Eye Diseases
Specialized imaging techniques support research on vision‑threatening ocular disorders.
- Neovascular age‑related macular degeneration
- Macular edema secondary to central retinal vein occlusion
- Diabetic retinopathy requiring anti‑VEGF therapy
Clinical programs assess the efficacy of intravitreal agents, laser interventions, and extended dosing schedules to improve visual outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 20 therapeutic areas and 15 of 255 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 242 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 53 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG6active
lock +52 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG10trials
lock +32 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniklinikum Salzburg
lock Showing 1 of 173 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 255 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 14 | Unknown | 2013-10-18 | 2025-10-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
